Fisons pentamidine
Executive Summary
Firm says FDA is actively reviewing the Treatment IND application and the NDA for aerosolized pentamidine as evidenced by the agency's impending audits of the clinical trial sites in Canada. FDA recently extended the time the agency has to consider the Treatment IND application by an additional 30 days from the April 30 deadline. . .